[Hemorheologic therapy applications in coronary heart disease].
A significant correlation was found between heightened plasma viscosity and increased red blood cell aggregation and the severity of coronary artery disease. At low shear rates and exhausted vasomotion these rheological factors can cause a reversible loss of fluidity. The reduced fluidity may induce a limitation in microcirculatory flow due to the viscus resistance. Rheological treatments aim at restoration of impaired perfusion by decreasing plasma viscosity and thus diminishing red blood cell aggregation. Further therapeutic measures tend to improve red blood cell deformability. Because of limited coronary reserve in coronary artery disease hemodilution therapy is contraindicated except the cases with polyglobulia. Thrombolytic therapy in acute myocardial infarction causes a significant reduction of plasma viscosity and red cell aggregation for at least 72 hours. This improvement in blood fluidity may beneficially influence the reperfusion of ischemic areas. A therapy with orally active hemorheological drugs (pentoxifylline and buflomedil) can be discussed as an additive treatment in severe angina pectoris refractory to specific medical therapy, since these drugs increase fluidity and inhibit platelet aggregation. The defibrination may cause thrombotic and bleeding complications in the early phase of treatment. Coronary small vessel disease represents a rare type of coronary heart disease. This disease is defined by normal epicardial coronaries and reduced coronary artery reserve. In disorders of coronary microcirculation with abnormal rheology (Waldenstrom's macroglobulinemia) rheological treatment is a rational and causal therapy.
D001809:Blood Viscosity; D003326:Coronary Circulation; D003327:Coronary Disease / Q000097:blood* / Q000628:therapy; D004903:Erythrocyte Aggregation; D004907:Erythrocyte Deformability; D005260:Female; D005340:Fibrinogen / Q000032:analysis; D005342:Fibrinolysis; D006438:Hemodilution; D006801:Humans; D008297:Male; D008833:Microcirculation / Q000503:physiopathology; D008875:Middle Aged; D010431:Pentoxifylline / Q000627:therapeutic use; D011759:Pyrrolidines / Q000627:therapeutic use; D012212:Rheology; D014665:Vasodilator Agents / Q000627:therapeutic use
D011759:Pyrrolidines; D014665:Vasodilator Agents; D005340:Fibrinogen; D010431:Pentoxifylline; C010651:buflomedil
Hämorheologisch-therapeutische Anwendungsmöglichkeiten bei der koronaren Herzerkrankung.